Rafael Holdings Inc Ordinary Shares - Class B RFL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL
Rafael Holdings to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Corporate Update
Rafael Holdings Announces Submission of New Drug Application to FDA for Trappsol® Cyclo™ (remibetadex) for the Treatment of Niemann-Pick Disease Type C
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL
Trading Information
- Previous Close Price
- $0.90
- Day Range
- $0.78–0.97
- 52-Week Range
- $0.78–3.96
- Bid/Ask
- $0.80 / $0.93
- Shares Outstanding
- 52.18M
- Market Cap
- $47.99M
- Volume/Avg
- 156,485 / 140,133
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 54.08
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.
- Sector
- Real Estate
- Industry
- Real Estate Services
- Stock Style Box
- Small Value
- Total Number of Employees
- 17
Valuation
Metric | RFL |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.72 |
Price/Sales | 54.08 |
Price/Cash Flow | — |
Price/Earnings
RFL
Financial Strength
Metric | RFL |
|---|---|
Quick Ratio | 2.05 |
Current Ratio | 2.35 |
Interest Coverage | −86.70 |
Quick Ratio
RFL
Profitability
Metric | RFL |
|---|---|
Return on Assets (Normalized) | −27.01% |
Return on Equity (Normalized) | −33.31% |
Return on Invested Capital (Normalized) | −32.31% |
Return on Assets
RFL
Real Estate Services Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| CBRE Group Inc Class A CBRE | LOCK|M>%gn#% | LOCK|Y%qm | $37B | |||
| KE Holdings Inc ADR BEKE | LOCK|!?qr>MF | LOCK|tmHHN | $20B | |||
| Sumitomo Realty & Development Co Ltd SURDF | — | LOCK|$% | $19B | |||
| Sumitomo Realty & Development Co Ltd ADR SURYY | — | LOCK|??m | $19B | |||
| Swire Properties Ltd SWPFF | — | LOCK|%!f!b | $19B | |||
| Cellnex Telecom SA ADR CLLNY | — | LOCK|mbFh> | $18B | |||
| Cellnex Telecom SA CLNXF | — | LOCK|Hxq& | $18B | |||
| Jones Lang LaSalle Inc JLL | LOCK|#^?!hLr | LOCK|zNPf | $16B | |||
| CoStar Group Inc CSGP | LOCK|!TR%qx | LOCK|&Q@@Y | $12B | |||
| Cushman & Wakefield Ltd CWK | LOCK|MZ^%>? | LOCK|&$t | $3B |